BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2030

DelveInsight’s ‘BRAF Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted BRAF Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

BRAF Mutated NSCLC Understanding
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer accounted for approximately 85% of all lung cancers. It can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas. In these subtypes adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.

There are several mutation associated with NSCLC but the most common are EGFR, KRAS, ROS-1 , BRAF , BRAF , PD-L1 expression and others. Among all the mutations BRAF accounted for approximately 5% of the total cases of NSCLC.

BRAF mutated NSCLC is now recognized as a rare form of lung cancer. The biologic behavior of BRAF mutated lung tumors tends to be more aggressive. The one unique aspects of BRAF mutated NSCLC, which differentiates it from other molecularly driven tumors such as EGFR, ALK, and ROS1, is that patients with BRAF V600E-mutant NSCLC tend to be patients with a smoking history. The BRAF gene encodes for a serine/threonine kinase that belongs to the RAS-RAF-MEK-ERK axis that regulates cellular growth.

For diagnosis of mutation associated with NSCLC a laboratory test is done to check for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Molecular tests check for certain gene or chromosome changes that occur in NSCLC.

Epidemiology Perspective by DelveInsight
The BRAF mutated NSCLC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The BRAF mutated NSCLC epidemiology data are studied through BRAF mutated NSCLC possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted BRAF mutated NSCLC epidemiology [segmented as Total Incident Cases of NSCLC, Total Incident Cases of NSCLC Patients by Histology, Total Diagnosed Cases of NSCLC Patients by Stages, Total NSCLC Cases of Patients by Genetic mutation/Biomarkers, and Treated Patient Pool of NSCLC] scenario of BRAF mutated NSCLC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

BRAF Mutated NSCLC Detailed Epidemiology Segmentation
• In histology-specific cases of NSCLC, Adenocarcinoma accounts for highest number of cases, i.e., approximately 47% followed by Squamous Cell Carcinoma and Large Cell Carcinoma.
• In genetic-mutation specific cases of NSCLC, most number of cases is from PD-L1 followed by KRAS, and EGFR. On the other hand, ROS-1 accounted for least number of cases whereas BRAF accounted for approximately 5% of cases.
• The total incident cases of BRAF mutated NSCLC in the 7MM were found to be 19,275 in 2017 which is expected to grow during the study period, i.e., 2017–2030
• Estimates shows that the highest incident population of BRAF mutated NSCLC are in the United States, followed by Germany, United Kingdom, and France in 2017.
• The United States accounted for approximately 8,979 cases of BRAF NSCLC in 2017.
• The total cases of BRAF mutated NSCLC in Germany, France, Italy, Spain and the UK was found to be around 2,666, 1,880, 1,592, 1,083, and 2,075, respectively in 2017.

Scope of the Report
• The BRAF mutated NSCLC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The BRAF mutated NSCLC Report and Model provide an overview of the risk factors and global trends of BRAF mutated NSCLC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of BRAF mutated NSCLC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of BRAF mutated NSCLC.
• The report provides the segmentation of the NSCLC epidemiology by incident cases of NSCLC patients by histology in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by diagnosed cases of NSCLC patients by stages in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by genetic mutation/biomarkers in the 7MM.
• The report provides the segmentation of the NSCLC epidemiology by treated patient pool of NSCLC in the 7MM.

Report Highlights
• 11-Year Forecast of BRAF mutated NSCLC epidemiology
• 7MM Coverage
• Total Incident Cases of NSCLC
• Incident Cases according to segmentation: Histology, Stage, Genetic Mutation/Biomarker
• Treated cases of NSCLC

KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over BRAF mutated NSCLC scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to BRAF mutated NSCLC?
• What are the key findings pertaining to the BRAF mutated NSCLC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of BRAF mutated NSCLC across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of BRAF mutated NSCLC?

Reasons to buy
The BRAF mutated NSCLC Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global BRAF mutated NSCLC market
• Quantify patient populations in the global BRAF mutated NSCLC market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for BRAF mutated NSCLC therapeutics in each of the markets covered
• Understand the magnitude of BRAF mutated NSCLC population by its severity
• The BRAF mutated NSCLC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The BRAF mutated NSCLC Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Total cases of BRAF mutated NSCLC in the 7MM was assessed to be 19,275 in 2017, and are expected to increase during the study period. Among the European 5 countries, the Germany had highest incident population of BRAF NSCLC, followed by United Kingdom and France. On the other hand, Spain had the lowest incident population of BRAF NSCLC, in 2017 among EU-5 countries. Furthermore, Japan accounts for about 5% of the total 7MM incident population of BRAF NSCLC (in 2017).


1. Key Insights
2. Executive Summary of BRAF NSCLC Epidemiology
3. BRAF Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
3.1. Introduction
3.1.1. Cellular Classification of NSCLC
3.1.2. Signs and Symptoms of NSCLC
3.1.3. Risk Factors of Lung Cancer
3.1.4. Causes of NSCLC
3.1.5. Disease Biology: NSCLC
4. Diagnosis of NSCLC
4.1. Diagnostic Algorithm for NSCLC
4.2. Stages of NSCLC
4.3. Staging System
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Incident cases of NSCLC patients in the 7MM
5.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
5.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
5.4. The United States Epidemiology
5.4.1. Total Incident cases of NSCLC patients in the United States
5.4.2. Total Incident cases of NSCLC patients by Histology in the United States
5.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
5.4.4. Total Incident cases of BRAF Mutated NSCLC in the United States
6. EU-5 Epidemiology
6.1. Germany
6.1.1. Total Incident cases of NSCLC patients in Germany
6.1.2. Total Incident cases of NSCLC patients by Histology in Germany
6.1.3. Total Diagnosed cases of NSCLC patients by Stages in Germany
6.1.4. Total Incident cases of BRAF Mutated NSCLC in Germany
6.2. France
6.2.1. Total Incident cases of NSCLC patients in France
6.2.2. Total Incident cases of NSCLC patients by Histology in France
6.2.3. Total Diagnosed cases of NSCLC patients by Stages in France
6.2.4. Total Incident cases of BRAF Mutated NSCLC in France
6.3. Italy
6.3.1. Total Incident cases of NSCLC patients in Italy
6.3.2. Total Incident cases of NSCLC patients by Histology in Italy
6.3.3. Total Diagnosed cases of NSCLC patients by Stages in Italy
6.3.4. Total Incident cases of BRAF Mutated NSCLC in Italy
6.4. Spain
6.4.1. Total Incident cases of NSCLC patients in Spain
6.4.2. Total Incident cases of NSCLC patients by Histology in Spain
6.4.3. Total Diagnosed cases of NSCLC patients by Stages in Spain
6.4.4. Total Incident cases of BRAF Mutated NSCLC in Spain
6.5. The United Kingdom
6.5.1. Total Incident cases of NSCLC patients in the United Kingdom
6.5.2. Total Incident cases of NSCLC patients by Histology in the United Kingdom
6.5.3. Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom
6.5.4. Total Incident cases of BRAF Mutated NSCLC in the United Kingdom
7. Japan Epidemiology
7.1. Japan
7.1.1. Total Incident cases of NSCLC patients in Japan
7.1.2. Total Incident cases of NSCLC patients by Histology in Japan
7.1.3. Total Diagnosed cases of NSCLC patients by Stages in Japan
7.1.4. Total Incident cases of BRAF Mutated NSCLC in Japan
8. Appendix
8.1. Bibliography
9. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Table 1 Summary of BRAF Non-small-cell Lung Cancer (NSCLC) Epidemiology and Key Events (2017–2030)
Table 2 TNM Staging of NSCLC
Table 3 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Table 4 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Table 5 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Table 6 Total Incident cases of NSCLC patients in the United States (2017–2030)
Table 7 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Table 8 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Table 9 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Table 10 Total Incident cases of NSCLC patients in Germany (2017–2030)
Table 11 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Table 12 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Table 13 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Table 14 Total Incident cases of NSCLC patients in France (2017–2030)
Table 15 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Table 16 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Table 17 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Table 18 Total Incident cases of NSCLC patients in Italy (2017–2030)
Table 19 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Table 20 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Table 21 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Table 22 Total Incident cases of NSCLC patients in Spain (2017–2030)
Table 23 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Table 24 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Table 25 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Table 26 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Table 27 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Table 28 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Table 29 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Table 30 Total Incident cases of NSCLC patients in Japan (2017–2030)
Table 31 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Table 32 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Table 33 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)
Figure 1 BRAF NSCLC SWOT Analysis
Figure 2 Major Types of NSCLC
Figure 3 Sign and Symptoms of NSCLC
Figure 4 Risks Factors of NSCLC
Figure 5 Alterations in Targetable Oncogenic Pathways in LUAD and LUSC
Figure 6 Schematic Illustration of the NSCLC Staging
Figure 7 Stage IA Lung Cancer
Figure 8 Stage IB Lung Cancer
Figure 9 Stage IIA Lung Cancer
Figure 10 Stage IIB Lung Cancer
Figure 11 Stage IIIA Lung Cancer
Figure 12 Stage IIIB Lung Cancer
Figure 13 Stage IVA Lung Cancer
Figure 14 Global Heat Map of Lung Cancer
Figure 15 Total Incident cases of NSCLC patients in the 7MM (2017–2030)
Figure 16 Total Incident cases of NSCLC patients by Histology in the 7MM (2017–2030)
Figure 17 Total Diagnosed cases of NSCLC patients by Stages in the 7MM (2017–2030)
Figure 18 Total Incident cases of NSCLC patients in the United States (2017–2030)
Figure 19 Total Incident cases of NSCLC patients by Histology in the United States (2017–2030)
Figure 20 Total Diagnosed cases of NSCLC patients by Stages in the United States (2017–2030)
Figure 21 Total Incident cases of BRAF Mutated NSCLC in the United States (2017–2030)
Figure 22 Total Incident cases of NSCLC patients in Germany (2017–2030)
Figure 23 Total Incident cases of NSCLC patients by Histology in Germany (2017–2030)
Figure 24 Total Diagnosed cases of NSCLC patients by Stages in Germany (2017–2030)
Figure 25 Total Incident cases of BRAF Mutated NSCLC in Germany (2017–2030)
Figure 26 Total Incident cases of NSCLC patients in France (2017–2030)
Figure 27 Total Incident cases of NSCLC patients by Histology in France (2017–2030)
Figure 28 Total Diagnosed cases of NSCLC patients by Stages in France (2017–2030)
Figure 29 Total Incident cases of BRAF Mutated NSCLC in France (2017–2030)
Figure 30 Total Incident cases of NSCLC patients in Italy (2017–2030)
Figure 31 Total Incident cases of NSCLC patients by Histology in Italy (2017–2030)
Figure 32 Total Diagnosed cases of NSCLC patients by Stages in Italy (2017–2030)
Figure 33 Total Incident cases of BRAF Mutated NSCLC in Italy (2017–2030)
Figure 34 Total Incident cases of NSCLC patients in Spain (2017–2030)
Figure 35 Total Incident cases of NSCLC patients by Histology in Spain (2017–2030)
Figure 36 Total Diagnosed cases of NSCLC patients by Stages in Spain (2017–2030)
Figure 37 Total Incident cases of BRAF Mutated NSCLC in Spain (2017–2030)
Figure 38 Total Incident cases of NSCLC patients in the United Kingdom (2017–2030)
Figure 39 Total Incident cases of NSCLC patients by Histology in the United Kingdom (2017–2030)
Figure 40 Total Diagnosed cases of NSCLC patients by Stages in the United Kingdom (2017–2030)
Figure 41 Total Incident cases of BRAF Mutated NSCLC in the United Kingdom (2017–2030)
Figure 42 Total Incident cases of NSCLC patients in Japan (2017–2030)
Figure 43 Total Incident cases of NSCLC patients by Histology in Japan (2017–2030)
Figure 44 Total Diagnosed cases of NSCLC patients by Stages in Japan (2017–2030)
Figure 45 Total Incident cases of BRAF Mutated NSCLC in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook